title: Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors.
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Poirier
authors.forename: Jean-Baptiste
authors.initials: JB
authors.lastname: Guiard-Schmid
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Meynard
authors.forename: Philippe
authors.initials: P
authors.lastname: Bonnard
authors.forename: Ouahiba
authors.initials: O
authors.lastname: Zouai
authors.forename: Tuna
authors.initials: T
authors.lastname: Lukiana
authors.forename: Patrice
authors.initials: P
authors.lastname: Jaillon
authors.forename: Pierre-Marie
authors.initials: PM
authors.lastname: Girard
authors.forename: Gilles
authors.initials: G
authors.lastname: Pialoux
mesh_terms: D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D000069446:Atazanavir Sulfate; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D009842:Oligopeptides / Q000627:therapeutic use*; D011446:Prospective Studies; D011725:Pyridines / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use*
chemical_list: D044966:Anti-Retroviral Agents; D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D018894:Reverse Transcriptase Inhibitors; D000069446:Atazanavir Sulfate; D019438:Ritonavir